Navigation Links
Luminex Corporation Reports First Quarter 2013 Results

AUSTIN, Texas, April 29, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced financial results for the first quarter ended March 31, 2013.  Financial and operating highlights include the following:

  • Consolidated first quarter revenue was $53.2 million, a 9 percent increase over the first quarter of 2012
  • Consolidated gross profit margin was 71 percent for the first quarter of 2013, compared to 69 percent for the first quarter of 2012
  • Non-GAAP net income for the first quarter was $7.9 million or $0.19 per diluted share. This compares to non-GAAP net income of $6.6 million, or $0.15 per diluted share for the first quarter of 2012. GAAP net loss for the first quarter was $2.5 million, or ($0.06) per diluted share.after a charge of $7.0 million associated with finalizing the termination of our molecular distribution agreements. This compares to GAAP net income of $3.5 million, or $0.08 per diluted share in the first quarter of 2012 (see the reconciliation of GAAP to non-GAAP set forth on page 7)
  • Received FDA clearance for the xTAG Gastrointestinal Pathogen Panel (xMAP® GPP™) on the LX200 system in January and on the MAGPIX system in April
  • Signed a collaboration and license agreement with Merck (NYSE: MRK) to develop a companion diagnostic that will help screen patients into Merck's lead investigational candidate drug study for Alzheimer's disease (AD)
  • (Logo:

    "Our royalty revenue grew 23% while our total cumulative shipments of multiplexing analyzers expanded to almost 10,000 units, or 11% over the year ago period, both of which indicate the strong ongoing demand for our proprietary technology," said Patrick J. Balthrop, president and chief executive officer of Luminex. "Furthermore, the company's successful transition to a direct molecular diagnostic sales force, effective January 1, 2013, was an important step in our ability to directly control the growth of our assay revenues going forward. We now have direct coverage of our molecular diagnostic products in the U.S. and major markets internationally. The customer response has been very positive," added Balthrop. "In other strategic initiatives, we continue to make good progress with our unique sample to answer system, called Project ARIES, which we will be demonstrating to key opinion leaders at the upcoming Clinical Virology Symposium in Florida.

    "We continue to be pleased with the expansion of our product offerings in infectious disease and genetic testing, particularly with the recent FDA clearance of GPP running on MAGPIX, our lower cost multiplexing analyzer. With new assays like GPP and the exciting portfolio from Luminex Madison, we are positioned for continued growth," Balthrop concluded. REVENUE SUMMARY(in thousands, except percentages)Three Months EndedMarch 31,Variance20132012($)(%)(unaudited)System sales

    $   6,557$   6,998$   (441)-6%Consumable sales

    11,89711,900(3)0%Royalty revenue

    10,1098,2421,86723%Assay revenue

    18,32417,2971,0276%All other revenue

    6,3134,2902,02347%$ 53,200$ 48,727$ 4,4739%"We are pleased with the overall financial performance in the first quarter of 2013, as Luminex transitions to a direct molecular diagnostic salesforce and invests in exciting strategic programs, like Project ARIES," said Harriss T. Currie, senior vice president and chief financial officer. "As reviewed previously, operating expenses for the current quarter included a $7.0 million charge attributable to finalizing the termination of our molecular diagnostic distribution arrangements.  If you exclude this charge, operating margin for the first quarter would be 10%. Investment in our new Project Aries system was robust during the quarter and added just over $3 million to R&D expenses for our ARP segment during the period."LUMINEX CORPORATIONREPORTABLE SEGMENT HIGHLIGHTS(in thousands, except percentages)Three Months EndedMarch 31,Variance20132012($)(%)(unaudited)RevenueTechnology and strategic partnerships

    $ 31,869$ 30,209$ 1,6605%Assays and related products

    21,33118,5182,81315%Total Revenue

    53,20048,7274,4739%Operating income (loss)Technology and strategic partnerships

    7,6817,2304516%Assays and related products

    (9,233)(1,622)(7,611)-469%Total Operating income (loss)

    (1,552)5,608(7,160)-128%FINANCIAL OUTLOOK AND GUIDANCE The Company reaffirms its 2013 annual revenue guidance of between $220 and $230 million.

    CONFERENCE CALL Management will host a conference call to discuss the operating highlights and financial results for the first quarter ended March 31, 2013, on Monday, April 29, 2013, at 4:00 p.m. Central time/ 5:00 p.m. Eastern time.  The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

    Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry.  The Company's xMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets.  The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.  Further information on Luminex or xMAP can be obtained on the Internet at

    Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding: the expansion of our installed base of multiplexing systems; our efforts to sell our molecular diagnostic products directly to end users; the development progress of our pipeline products, including Project Aries, NeoPlex4 and the NeoPlex System; anticipated FDA clearance of our products, including NeoPlex4 and the NeoPlex system and Project Aries; market acceptance of our products, including Gastrointestinal Pathogen Panel, Cystic Fibrosis, RVP FAST, 2D6 and other genetic testing products; our collaboration with Merck regarding an Alzheimer's diagnostic assay; the ability of our investment in current initiatives and new products to deliver high performance solutions, and drive long-term value for our shareholders; and, projected 2013 revenue. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements.  Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products and technology, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, our ability to sell products directly to end users, our ability to satisfy market needs with products that we sell, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, the uncertainty regarding the outcome or expense of any litigation brought against Luminex, risks relating to Luminex's foreign operations, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies, or selected assets into our consolidated business operations, including the ability to recognize the benefits of our acquisitions, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission.  The forward-looking statements, including the financial guidance and 2013 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


    Harriss T. Currie

    Matthew ScaloSr. Vice President, Finance and Chief Financial Officer

    Sr. Director, Investor Relations512-219-8020  

     LUMINEX CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)March 31,December 31,20132012(unaudited)ASSETSCurrent assets:Cash and cash equivalents

    42,789Short-term investments

    6,59913,607Accounts receivable, net

    25,12733,273Inventories, net

    32,33229,937Deferred income taxes

    5,8186,148Prepaids and other

    4,6934,388Total current assets

    128,858130,142Property and equipment, net

    26,58826,229Intangible assets, net

    64,19365,218Deferred income taxes

    12,81212,819Long-term investments



    9,2868,463Total assets

    $   292,876$
    296,999LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    9,650Accrued liabilities

    16,39712,690Deferred revenue

    4,5244,134Current portion of long term debt

    1,4091,138Total current liabilities

    30,25427,612Long-term debt

    1,4031,702Deferred revenue


    5,1135,085Total liabilities

    39,56137,332Stockholders' equity:Common stock

    4141Additional paid-in capital

    289,662293,392Accumulated other comprehensive gain

    9901,101Accumulated deficit

    (37,378)(34,867)Total stockholders' equity

    253,315259,667Total liabilities and stockholders' equity

    $   292,876$

     LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)Three Months EndedMarch 31,20132012(unaudited)Revenue

    $ 53,200$ 48,727Cost of revenue

    15,24314,967Gross profit

    37,95733,760Operating expenses:Research and development

    12,71410,137Selling, general and administrative

    25,76616,915Amortization of acquired intangible assets

    1,0291,100Total operating expenses

    39,50928,152(Loss) income from operations

    (1,552)5,608Interest expense from long-term debt

    (28)(59)Other income, net

    (7)57(Loss) income before income taxes

    (1,587)5,606Income taxes

    (924)(2,079)Net (loss) income

    $  (2,511)$   3,527Net (loss) income per share, basic

    $   (0.06)$
    .09Shares used in computing net (loss) income per share, basic

    40,88740,919Net (loss) income per share, diluted

    $   (0.06)$
    .08Shares used in computing net (loss) income per share, diluted


     LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)Three Months EndedMarch 31,20122011(unaudited)Cash flows from operating activities:Net (loss) income

    $  (2,511)$   3,527Adjustments to reconcile net (loss) income to net cash provided by operating activities:Depreciation and amortization

    3,8043,522Stock-based compensation

    2,4322,643Deferred income tax expense

    700553Excess income tax expense (benefit) from employee stock-based awards

    274(297)Loss on disposal of assets


    198232Changes in operating assets and liabilities:Accounts receivable, net

    8,095(4,013)Inventories, net

    (2,404)133Other assets

    (896)40Accounts payable

    (1,731)(486)Accrued liabilities

    1,777(6,026)Deferred revenue

    263143Net cash provided by (used in) operating activities

    10,019(29)Cash flows from investing activities:Purchases of available-for-sale securities

    (2,995)(8,999)Sales and maturities of available-for-sale securities

    13,0338,515Purchase of property and equipment

    (2,791)(1,596)Proceeds from sale of assets

    31-Acquired technology rights

    (930)-Net cash provided by (used in) investing activities

    6,348(2,080)Cash flows from financing activities:Proceeds from employee stock plans and issuance of common stock

    1,401657Payments for stock repurchases

    (5,775)(5,448)Excess income tax (expense) benefit from employee stock-based awards

    (274)297Net cash used in financing activities

    (4,648)(4,494)Effect of foreign currency exchange rate on cash

    (219)151Change in cash and cash equivalents

    11,500(6,452)Cash and cash equivalents, beginning of period

    42,78958,282Cash and cash equivalents, end of period

    $ 54,289$ 51,830 

     LUMINEX CORPORATIONNON-GAAP RECONCILIATION(in thousands)Three Months EndedMarch 31,20132012(unaudited)Net loss

    $ (2,511)$ 3,527Stock-based compensation

    2,4322,643Amortization of acquired intangible assets

    1,0291,100Costs associated with legal proceedings

    113-Resolution of molecular diagnostic distribution agreements

    7,000-Severance costs

    33071Income tax effect of above adjusting items

    (535)(735)Adjusted net income

    $  7,858$ 6,606Adjusted net income per share, basic

    .19$   0.16Shares used in computing adjusted net income per share, basic

    40,88740,919Adjusted net income per share, diluted

    .19$   0.15Shares used in computing adjusted net income per share, diluted

    41,75042,805The Company makes reference in this release to "non-GAAP net income" which excludes the impact of certain recurring and non-recurring expenses. The Company believes that excluding these items and their related tax effects from its financial results reflects operating results that are more indicative of the Company's ongoing operating performance while improving comparability to prior periods, and, as such may provide investors with an enhanced understanding of the Company's past financial performance and prospects for the future. This information is not intended to be considered in isolation or as a substitute for income from operations, net income, net income per share or expense information prepared in accordance with GAAP.

    SOURCE Luminex Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Luminex Corporation Reports First Quarter 2012 Results
    2. Luminex Corporation Announces Agreement to Acquire GenturaDx
    3. Luminex Corporation Second Quarter Earnings Release Scheduled for July 30, 2012
    4. Luminex Corporation Reports Second Quarter 2012 Results
    5. Luminex Corporation and University Hospital of Wales Collaborate During Olympic Games
    6. Luminex Corporation Awarded $11 Million Contract by Defense Threat Reduction Agency (DTRA)
    7. Luminex Corporation Recognized as Best Technology Company in Austin
    8. Luminex Corporation Hosts 10th Annual Planet xMAP Symposium in Monaco
    9. Luminex Corporation To Present At Upcoming Investment Conferences In September
    10. Luminex Corporation Reports Third Quarter 2012 Results
    11. Luminex Corporation To Present At Leerink Swann Global Healthcare Conference
    Post Your Comments:
    (Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at ...
    (Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
    (Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
    (Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
    (Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
    (Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
    Breaking Medicine News(10 mins):